Go and get connected to this global research system. Graphic by Miguel Tovar/University of Houston

We have all needed scholarly articles to cite in our academic careers. Now, there is a place where researchers can get millions of them, all on one site.

Named after the Library of Alexandria, OpenAlex is an index of over 200 million scientific documents including publication sources, author information and research topics that can be used to conduct studies and build research tools. According to its founders, the goal of this index is to “create a comprehensive, interlinked database of the global research system.”

So, how can researchers use this database and why is it beneficial?

More data

After Microsoft announced the closure of the Microsoft Academic Graph, a non-profit scholarly service firm, OurResearch, created OpenAlex.

OpenAlex gets its information from MAG and other sources. It also integrates with Unpaywall, which has over 30 million articles. This allows for access to much more information.

There are not just free articles to read, but OpenAlex will also tell you the license and the version of the articles.

OpenAlex updates every two weeks and brings in even more data from its other sources. With all this extra information, researchers have everything they need to conduct studies using scholarly articles by their peers.

Free and easy to use

Who doesn’t like free stuff? Everyone does! OpenAlex is 100% free to use. You don’t have to register for anything or sign in every time. You just go to the website and look for what you need.

According to one researcher, “for somebody who is more computer savvy, MAG might be easier… For researchers who want to try small projects on their own, OpenAlex will be way easier to start with.”

While it can take several days to a week to get started on MAG, it only takes a few hours on OpenAlex.

What's the big idea?

If you’re a researcher looking for an open index of millions of scholarly articles, you should try OpenAlex. A more user-friendly search engine will be added in February, making it that much easier to use the site. OpenAlex’s goal is to make connections between an expansive database of scholarly articles. Go and get connected to this global research system.

------

This article originally appeared on the University of Houston's The Big Idea. Cory Thaxton, the author of this piece, is the communications coordinator for The Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.